Naveen Pemmaraju, MD
Dr. Pemmaraju is Associate Professor in the Department of Leukemia at MD Anderson Cancer Center in Houston.
Articles by Naveen Pemmaraju, MD
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
The panel considered whether it’s time for new response criteria in myelofibrosis such as anemia improvement.
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.
Experts discuss emerging therapeutic targets, the impact of recently approved agents, and incorporating them into practice.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.